Cita APA

Rimawi, M. F., De Angelis, C., Contreras, A., Pareja, F., Geyer, F. C., Burke, K. A., . . . Schiff, R. (2017). Low PTEN Levels and PIK3CA Mutations Predict Resistance to Neoadjuvant Lapatinib and Trastuzumab without Chemotherapy in Patients with HER2 Over-Expressing Breast Cancer. Breast Cancer Res Treat.

Citación estilo Chicago

Rimawi, Mothaffar F., et al. "Low PTEN Levels and PIK3CA Mutations Predict Resistance to Neoadjuvant Lapatinib and Trastuzumab Without Chemotherapy in Patients With HER2 Over-Expressing Breast Cancer." Breast Cancer Res Treat 2017.

Cita MLA

Rimawi, Mothaffar F., et al. "Low PTEN Levels and PIK3CA Mutations Predict Resistance to Neoadjuvant Lapatinib and Trastuzumab Without Chemotherapy in Patients With HER2 Over-Expressing Breast Cancer." Breast Cancer Res Treat 2017.